Identification of Novel Mutations in the N Gene of SARS-CoV-2 That Adversely Affect the Detection of the Virus by Reverse Transcription-Quantitative PCR

Accurate and timely diagnosis of SARS-CoV-2 is a critical step toward controlling the viral spread, since it facilitates the identification and isolation of infected individuals. Mutations in the primer-/probe-binding sites may lead to false-negative results.

at the 59 end and a triple nucleotide deletion (28896CTAdel) at the 39 end of the forward primer-binding site (3) were detected in the suspected samples (Fig. 1A). Interestingly, one nucleotide substitution (G28314T) was also observed in the probe-binding region for the U.S. CDC nCoV N1 RT-qPCR assay, although the mismatch did not impair detection in the confirmatory test (Fig. 1A).
To estimate the frequency of both the substitutions and the deletion among Bangladeshi strains, we retrieved all complete SARS-CoV-2 sequences (1,247 sequences) from the GISAID EpiCoV database (28 April 2021). Nucleotide mismatches in the Bangladeshi sequences are described in Fig. 1B. In particular, the GGG28881AAC substitution and the 28896CTA deletion were simultaneously detected in 11 sequences (0.88%). According to a local BLASTN search, 40 isolates carry both the 28881AAC variant and the 28896CTA deletion. Based on the GISAID EpiCoV database, 48.8% (649,115/1,329,560) sequences contain the 28881AAC variant (5). Approximately 0.18% (n = 3,803) of the isolate sequences in GISAID contain the target 28896CTA deletion, and 1.54% of the genomes contain at least one mutation in the last pentanucleotides of the 39 primer region for the China CDC N RT-qPCR assay as reported by the GISAID EpiCoV database (5). Isolates containing both the 28881AAC variant and the 28896CTA deletion, which stopped detection of the N gene using the China CDC N RT-qPCR assay, originated from the United States, Australia, England, and Bangladesh. According to the U. S. CDC nCoV N1 RT-qPCR assay, the probe region contains about 10,105 single-nucleotide polymorphisms (SNPs). The G28314T substitution is carried by 39 and 25 sequences according to GISAID and BLASTN searches, respectively.
RNA viruses such as SARS-CoV-2 are prone to mutations associated with virulence and evolvability, traits considered beneficial for viruses. Mutations in the primer-and probe-binding regions may lead to false-negative diagnoses for SARS-CoV-2. Previous studies have claimed that a single mutation (C29200T or C29200A) in the probe-binding region of an isolate was associated with failure of the virus detection when using the U.S. CDC nCoV N1 RT-qPCR assay (6,7).
Our data show that SARS-CoV-2 variants carrying mutations in the primer-/probe-binding regions that impair RT-qPCR detection may have emerged and spread in the community. Our study suggests that mutations in the SARS-CoV-2 N gene RT-qPCR primer-binding sites might cause issues related to sensitivity and potentially underdiagnosis if we rely on an assay with only a single target. Mutations in the primer-/probe-binding regions of both targets could potentially result in false-negative detection. According to the GISAID update on common primer checks, the primer-/probe-binding regions for the targets of all WHO in-house SARS-CoV-2 diagnostic assays carried mutations, suggesting the need for continuous monitoring for mutations, especially when one of the RT-qPCR assays fails to detect SARS-CoV-2 (5). This study also highlights the importance of the use of RT-qPCR assays with at least two targets for SARS-CoV-2 detection. If symptomatic COVID-19 patients test negative using one assay, our findings strongly support retesting with another assay to avoid false-negative results.
Data availability. The sequence data have been submitted to GenBank (accession no. MZ379157 and MZ379158) and GISAID (accession no. EPI_ISL_1715168).
Ethical statement. This study has been approved by the research review board of icddr,b (protocol no. PR-20102).